Cas no 23739-88-0 (Triacetyl-b-cyclodextrin)

Triacetyl-β-cyclodextrin is a chemically modified derivative of β-cyclodextrin, where hydroxyl groups are acetylated to enhance its physicochemical properties. This modification improves solubility in organic solvents and increases lipophilicity, making it suitable for applications requiring hydrophobic guest molecule encapsulation. The acetyl groups also confer greater stability against enzymatic degradation compared to native cyclodextrins. Its cavity structure retains the host-guest complexation capability, enabling use in drug delivery, fragrance stabilization, and analytical chemistry. The derivative’s tailored hydrophobicity broadens compatibility with nonpolar compounds while maintaining the parent molecule’s molecular recognition properties. These characteristics make it a versatile excipient in formulations requiring controlled release or enhanced bioavailability.
Triacetyl-b-cyclodextrin structure
Triacetyl-b-cyclodextrin structure
Product Name:Triacetyl-b-cyclodextrin
CAS No:23739-88-0
MF:C84H112O56
MW:2017.7545
MDL:MFCD29127435
CID:240029
PubChem ID:87577570
Update Time:2025-06-08

Triacetyl-b-cyclodextrin Chemical and Physical Properties

Names and Identifiers

    • b-Cyclodextrin,2A,2B,2C,2D,2E,2F,2G,3A,3B,3C,3D,3E,3F,3G,6A,6B,6C,6D,6E,6F,6G-heneicosaacetate
    • Triacetyl-beta-cyclodextrin
    • Triacetyl-β-cyclodextrin
    • A-cyclodextrin
    • A-Cyclodextrin heneicosaacetate
    • Beta-Cyclodextrin Henicosaacetate
    • Triacetyl-
    • β-Cyclodextrin Henicosaacetate
    • [(1R,3R,6S,8S,11R,13S,16R,18S,21R,23S,26R,28S,31R,33S)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-Tet
    • Triacetyl-b-cyclodextrin
    • J-015198
    • MFCD29127435
    • 23739-88-0
    • AKOS026674406
    • NOPKOJDDVCBPTP-DJSZNTTKSA-N
    • D92534
    • MDL： MFCD29127435
    • Inchi： 1S/C84H112O56/c1-29(85)106-22-50-57-64(113-36(8)92)71(120-43(15)99)78(127-50)135-58-51(23-107-30(2)86)129-80(73(122-45(17)101)65(58)114-37(9)93)137-60-53(25-109-32(4)88)131-82(75(124-47(19)103)67(60)116-39(11)95)139-62-55(27-111-34(6)90)133-84(77(126-49(21)105)69(62)118-41(13)97)140-63-56(28-112-35(7)91)132-83(76(125-48(20)104)70(63)119-42(14)98)138-61-54(26-110-33(5)89)130-81(74(123-46(18)102)68(61)117-40(12)96)136-59-52(24-108-31(3)87)128-79(134-57)72(121-44(16)100)66(59)115-38(10)94/h50-84H,22-28H2,1-21H3/t50?,51?,52?,53?,54?,55?,56?,57-,58-,59-,60-,61-,62-,63+,64?,65?,66?,67?,68?,69?,70?,71?,72?,73?,74?,75?,76?,77?,78+,79+,80+,81+,82+,83-,84+/m1/s1
    • InChI Key： NOPKOJDDVCBPTP-QIIRDPIQSA-N
    • SMILES： O1[C@@]2([H])C([H])(C([H])([C@@]([H])(C([H])(C([H])([H])OC(C([H])([H])[H])=O)O2)O[C@@]2([H])C([H])(C([H])([C@@]([H])(C([H])(C([H])([H])OC(C([H])([H])[H])=O)O2)O[C@@]2([H])C([H])(C([H])([C@@]([H])(C([H])(C([H])([H])OC(C([H])([H])[H])=O)O2)O[C@@]2([H])C([H])(C([H])([C@@]([H])(C([H])(C([H])([H])OC(C([H])([H])[H])=O)O2)O[C@@]2([H])C([H])(C([H])([C@@]([H])(C([H])(C([H])([H])OC(C([H])([H])[H])=O)O2)O[C@]2([H])C([H])(C([H])([C@]([H])(C([H])(C([H])([H])OC(C([H])([H])[H])=O)O2)O[C@@]2([H])C([H])(C([H])([C@@]1([H])C([H])(C([H])([H])OC(C([H])([H])[H])=O)O2)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O)OC(C([H])([H])[H])=O

Computed Properties

  • Exact Mass: 2016.59000
  • Monoisotopic Mass: 2016.592
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 0
  • Hydrogen Bond Acceptor Count: 56
  • Heavy Atom Count: 140
  • Rotatable Bond Count: 49
  • Complexity: 3700
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 35
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • Surface Charge: 0
  • Tautomer Count: nothing
  • XLogP3: nothing
  • Topological Polar Surface Area: 682

Experimental Properties

  • Color/Form: Not determined
  • Density: 1.45
  • Melting Point: 204-206?°C (lit.)
  • Boiling Point: 1361.8°Cat760mmHg
  • Flash Point: 444.8°C
  • Refractive Index: 123 ° (C=1, CH3CN)
  • Solubility: Soluble in chloroform, DMF. Insoluble in water.
  • PSA: 681.52000
  • LogP: -3.24380
  • Solubility: Not determined
  • Optical Activity: [α]25/D +125°, c =?1 in chloroform

Triacetyl-b-cyclodextrin Security Information

  • Hazardous Material transportation number：NONH for all modes of transport
  • WGK Germany：3

Triacetyl-b-cyclodextrin Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd.
T1844-25G
Triacetyl-β-cyclodextrin
 23739-88-0 >97.0%(HPLC)
25g
 ￥2245.00 2024-04-17
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
X72055-5g
Triacetyl-β-cyclodextrin
 23739-88-0 ≥97%
5g
 ￥538.0 2023-09-05
SHANG HAI JI ZHI SHENG HUA Technology Co., Ltd.
X72055-1g
Triacetyl-β-cyclodextrin
 23739-88-0
1g
 ￥228.0 2021-09-07
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.
T867523-1g
Triacetyl-β-cyclodextrin
 23739-88-0 ≥97%
1g
 ￥199.00 2022-09-28
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.
T867523-5g
Triacetyl-β-cyclodextrin
 23739-88-0 ≥97%
5g
 ￥668.00 2022-09-28
SHANG HAI XIAN DING Biotechnology Co., Ltd.
T1844-25g
Triacetyl-b-cyclodextrin
 23739-88-0 97.0%(LC)
25g
 ￥1595.0 2022-06-10
abcr
AB142741-25 g
Triacetyl-beta-cyclodextrin, 97%; .
 23739-88-0 97%
25 g
 €376.50 2023-07-20
TRC
T737000-1000mg
Triacetyl-b-cyclodextrin
 23739-88-0
1g
 $115.00 2023-05-17
TRC
T737000-100mg
Triacetyl-b-cyclodextrin
 23739-88-0
100mg
 $ 71.00 2023-09-05
TRC
T737000-500mg
Triacetyl-b-cyclodextrin
 23739-88-0
500mg
 $87.00 2023-05-17

Triacetyl-b-cyclodextrin Related Literature

Additional information on Triacetyl-b-cyclodextrin

Triacetyl-β-Cyclodextrin (CAS No. 23739-88-0): A Versatile Compound in Pharmaceutical and Biomedical Applications

Triacetyl-β-cyclodextrin (CAS No. 23739-88-0) is a derivative of β-cyclodextrin, a cyclic oligosaccharide composed of seven glucose units. This compound has gained significant attention in the pharmaceutical and biomedical fields due to its unique properties and potential applications. In this article, we will delve into the structure, synthesis, properties, and recent advancements in the use of Triacetyl-β-cyclodextrin.

Structure and Synthesis

Triacetyl-β-cyclodextrin is synthesized by the acetylation of β-cyclodextrin, which involves the reaction of β-cyclodextrin with acetic anhydride in the presence of a catalyst. The resulting compound has three acetyl groups attached to the hydroxyl groups of the glucose units, enhancing its solubility and stability in various solvents. The molecular formula of Triacetyl-β-cyclodextrin is C36H60O30, with a molecular weight of approximately 1135.8 g/mol.

Properties and Mechanisms

Triacetyl-β-cyclodextrin exhibits several advantageous properties that make it a valuable compound in pharmaceutical formulations. One of its key features is its ability to form inclusion complexes with various guest molecules, such as drugs, fragrances, and dyes. This property is attributed to the hydrophobic cavity within the cyclodextrin ring, which can encapsulate hydrophobic molecules, thereby enhancing their solubility and stability.

The formation of inclusion complexes can also improve the bioavailability and controlled release of drugs. For instance, studies have shown that Triacetyl-β-cyclodextrin-drug complexes can enhance the oral bioavailability of poorly soluble drugs by increasing their dissolution rate and reducing their degradation in the gastrointestinal tract.

Applications in Pharmaceutical Formulations

Triacetyl-β-cyclodextrin has found extensive applications in pharmaceutical formulations due to its ability to improve drug delivery and stability. One notable application is in solid dispersions, where it is used as a carrier to enhance the solubility and dissolution rate of poorly soluble drugs. This approach has been successfully applied to improve the bioavailability of drugs such as itraconazole and griseofulvin.

In addition to solid dispersions, Triacetyl-β-cyclodextrin is used in liquid formulations to stabilize drugs that are prone to degradation or precipitation. For example, it has been used to stabilize insulin solutions by forming inclusion complexes that protect the protein from denaturation.

Clinical Trials and Research Findings

The potential benefits of Triacetyl-β-cyclodextrin-based formulations have been evaluated in several clinical trials. A recent study published in the Journal of Pharmaceutical Sciences investigated the use of Triacetyl-β-cyclodextrin-drug complexes for improving the oral bioavailability of a poorly soluble anticancer drug. The results showed a significant increase in drug absorption and a reduction in side effects compared to conventional formulations.

Another study published in the European Journal of Pharmaceutics and Biopharmaceutics explored the use of Triacetyl-β-cyclodextrin strong>-based nanoparticles for targeted drug delivery. The nanoparticles were designed to release the drug at specific sites within the body, thereby enhancing therapeutic efficacy and reducing systemic toxicity.

Safety and Regulatory Considerations

The safety profile of Triacetyl-β-cyclodextrin strong> has been extensively studied, and it is generally recognized as safe (GRAS) by regulatory agencies such as the U.S. Food and Drug Administration (FDA). However, like any pharmaceutical excipient, it should be used within established guidelines to ensure patient safety.

Clinical trials have shown that Triacetyl-β-cyclodextrin strong>-based formulations are well-tolerated by patients, with minimal adverse effects reported. Nevertheless, ongoing research is necessary to fully understand its long-term safety profile and potential interactions with other drugs or biological systems.

FUTURE DIRECTIONS AND CONCLUSIONS strong> p > < p >The future outlook for Triacetyl - β - cycl od extri n strong >is promising , with ongoing research exploring new applications and optimizing existing formulations . Advances in nanotechnology , targeted drug delivery , and personalized medicine are likely to further expand its utility in pharmaceutical development . p > < p >In conclusion ,< strong > Triac etyl - β - cycl od extri n strong > ( CAS No . 23739 - 88 - 0 ) is a versatile compound with significant potential in pharmaceutical and biomedical applications . Its unique properties , including enhanced solubility , stability , and improved drug delivery , make it an invaluable tool for developing more effective and safer therapeutic options . As research continues , we can expect even more innovative uses for this remarkable compound . p > article > < / response >

23739-88-0 (Triacetyl-b-cyclodextrin) Related Products

Recommended suppliers
HANGZHOU BAIS CHEMICAL TECHNOLOGY CO., LTD.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
HANGZHOU BAIS CHEMICAL TECHNOLOGY CO., LTD.
Nanjing Jubai Biopharm
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Nanjing Jubai Biopharm
Shenzhen GeneSeqTools Bioscience & Technology Co. Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Shenzhen GeneSeqTools Bioscience & Technology Co. Ltd.
Shenzhen Yaoyuan R&D Center Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shenzhen Yaoyuan R&D Center Co.,Ltd
Hubei Cuiyuan Biotechnology Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Hubei Cuiyuan Biotechnology Co.,Ltd